Sentences with phrase «in diseases of»

Uncontrolled calcium signaling and ROS in the mitochondria is behind a number of common diseases, such as stroke or heart attack, and is thought to play a role in diseases of aging such as neurodegenerative disease.

«Some GPCRs, for instance, are targeted by neurotransmitters, and their functions are compromised in diseases of the central nervous system, so it is possible that optical switches could also be of interest in the treatment of conditions such as depression or epilepsy.

While it's working, for now, in diseases of the liver, the field still needs to validate whether RNAi can work in other organs.

A small but growing number of studies now suggest that air pollutants may play a role in diseases of the gut.

«This is an innovative and promising approach for a bad, bad disease,» says Fred Gorelick, a clinician and researcher at Yale University who specializes in diseases of the pancreas.

It was High herself who approached Bennett with the insight that what had failed to work for hemophiliacs just might succeed in diseases of the eye.

«In these diseases of mitochondrial dysfunction, in a sense, it's a false starvation situation for the cell — there are plenty of nutrients, but because there's a block in the mitochondria's normal function, the mitochondria behave as if there's not enough oxygen,» says Chen, who with Birsoy, authored a paper in the journal Cell Reports describing this work.

Studies exploring how neurons mature are helping researchers to understand what goes wrong in diseases of brain development.

The point for PANS: In diseases of autoimmunity, where rogue immune cells are stuck in the brain, returning these lymphatic vessels to greater function may be a potent means of clearing up disease.

Rather, the pager is a symbol of Apstein's other life: as a gastroenterologist at Beth Israel Deaconess Medical Center, in Boston, where he specializes in diseases of the digestive tract, including the liver.

Christian existence is the common mission to proclaim the Incarnate Son in the power of the Spirit who extend their shared life with the Father to a world mired in the disease of sin.

Not exact matches

Cornell's mother suffered from heart disease through much of her life, and the two of them lived very modestly off her disability check in working - class White - stone, Queens.

About 69 million employees in the U.S. say they miss work because of health problems every year, which reduces economic output by $ 260 billion per year, according to the Centers for Disease Control and Prevention.

Made by companies like Gilead, AbbVie, Merck, and others, drugs that treat the disease are listed at tens of thousands of dollars in the U.S..

Heart disease is the leading cause of death for men and women in the U.S. Every year over 700,000 Americans have a heart attack and half of those are fatal.

«We're in a serious jam,» says Gerry Wright, director of the Michael DeGroote Institute for Infectious Disease Research at McMaster University.

«The potion is not a panacea — it does not have a magic power against all diseases,» said a researcher experienced in cockroach - related medicines at the Institute of Materia Medica at the Chinese Academy of Medical Sciences (CAMS) in Beijing.

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

Tehrani targeted the most conservative companies in the business, ones that had no presence in a particular class of disease targets, to entice those who might jump on the bandwagon later.

«It is our hope that by targeting people earlier, we will have a better chance of delaying or preventing the onset of the disease,» said BAI director Dr. Pierre N. Tariot in a statement.

The Bahamian - American physician and special adviser to the Carter Center is one of the key individuals responsible for the eradication of smallpox — a truly terrifying disease that in the 20th century alone killed as many as 300 million people.

Omada's digital therapeutics platform attempts to address disparate health care needs that can be particularly cumbersome for people at risk for chronic diseases like diabetes through a combination of data analytics, user engagement, and the broad goal of preventing these kinds of conditions from developing in the first place.

«If we determine that our [treatment] can prevent or delay the onset of symptoms in healthy yet high - risk populations, this would represent a tremendous breakthrough for those that may face this debilitating disease.»

They're also the sixth leading cause of chronic disease in the US.

A study of increases or decreases in rates of a disease across years, calculated for groups of people, is called an ecologic study.

Founded in 2011, Innovent has built a portfolio of 16 potential products for treating cancer, autoimmune disorders and other diseases, and seven of those are in clinical development.

In a recently recovered interview with Steve Jobs, he talks about the disease that grips most people, which he explains is «thinking that a really great idea is 90 percent of the work.

When considering the fact that in the US, 2,684,803 mothers had a vaginal birth and 1,258,581 mothers had a c - section in 2016, according to the Centers for Disease Control and Prevention, that's a lot of money going into the healthcare system just from maternity costs.

In a year that saw a terrible Ebola pandemic in Africa and the resurgence of Legionnaire's disease in New York, it's small wonder that life sciences and health - care companies are also leading the way for initial public offeringIn a year that saw a terrible Ebola pandemic in Africa and the resurgence of Legionnaire's disease in New York, it's small wonder that life sciences and health - care companies are also leading the way for initial public offeringin Africa and the resurgence of Legionnaire's disease in New York, it's small wonder that life sciences and health - care companies are also leading the way for initial public offeringin New York, it's small wonder that life sciences and health - care companies are also leading the way for initial public offerings.

The Chinese government financed nationwide studies into cockroaches» medical value that, after more than two decades of laboratory investigation and clinical trials, had discovered or confirmed dozens of disease - fighting proteins and biochemical compounds with huge potential value in medicine.

«Expanding our collaboration with Banner Alzheimer's Institute stands testament to our belief that preventing amyloid buildup is one of the most promising approaches to treating Alzheimer's disease,» said Novartis» chief medical officer, global head of drug development, and soon - to - be CEO Dr. Vas Narasimhan in a statement.

He also said that Theranos is at the forefront of a paradigm shift in health care, where the emphasis is moving from treating symptoms once a disease has manifested to stopping the illness before traditional symptoms are necessarily displayed.

, didn't smoke, didn't drink, ate healthy, had a resting heart rate below 50, normal blood pressure, cholesterol 120... toss me in a random pool of a thousand people and I would have been one of the last picked to win a «Who Is Most Likely to Suffer from Heart Disease?»

Eventually, the technology could help providers identify more individuals who are at risk of developing cardiovascular conditions — cardiovascular disease not only affects over 100 million people in the US, it is also the costliest disease in the nation, with associated costs reaching $ 555 billion in 2016, according to American Heart Association.

Following the death of a man in Texas who was infected with Ebola, hospitals across the country are bracing themselves for the possibility of having to manage the deadly disease.

Secondary goals included demonstrating efficacy of the vaccine in reducing the incidence of all symptomatic respiratory disease due to RSV.

Low - income Americans saw no improvements in blood pressure, their risk of heart disease, or a drop in the share of people who smoke between 2011 and 2014 compared with the period running from 1999 to 2004, according to a study published in the journal JAMA Cardiology.

Scanadu will also have anonymized access to all of its users» health data, which can be used for epidemiology — the study of the patterns of health and disease in defined geographic areas.

«They said, «Apart from the fact that improper reproduction of the DNA molecule causes genetic disease and deformities, we haven't understood anything else,»» says Mitra, who published his findings in the British Journal of Educational Technology last year.

According to data from the National Center for Health Statistics (NCHS), a branch of the Centers for Disease Control and Prevention, the life expectancy for a baby born in 2016 fell to 78.6 years, which is a small but statistically significant decline of 0.1 percent.

«Companies with lead programs in psychiatry, hematology, cardiovascular, and gastrointestinal diseases received the least amount of funding in 2016, with each category receiving well under $ 100 million,» writes BIO.

High percentages of those polled also believe A.I. can make significant advances in eradicating cancer and diseases, developing clean energy, improving education, and boosting global health and well - being.

Why have we made more progress on certain diseases while other mass - scale killers, like chronic obstructive pulmonary disease (COPD), are largely off of people's radars and so difficult to treat in an age of therapies which can resemble magic?

For one thing, «There are a lot of good drugs on the market for heart disease right now that come in generic form,» says Neil Lesser, a principal at Deloitte who specializes in the life sciences, in an interview with Fortune.

Brian Cheng, executive director at NWS Holdings, said: «We believe Medopad will succeed in revolutionizing the current convoluted methods of disease treatment and prevention into a more succinct ecosystem with the development of its artificial intelligence and big data gathering capabilities.»

• Rani Therapeutics, a San Jose, Calif. - based developer of a pill designed to replace injectable drug delivery for patients suffering from chronic diseases, raised $ 53 million in funding.

«Firearm - related deaths are the third leading cause of death overall among U.S. children aged 1 to 17 years, surpassing the number of deaths from pediatric congenital anomalies, heart disease, influenza and / or pneumonia, chronic lower respiratory disease, and cerebrovascular causes,» wrote the CDC in its report.

For a century and a half, epidemiology has been an effective strategy for tracing the root causes of infectious disease outbreaks — as John Snow demonstrated in 1854, when he painstakingly mapped cases of cholera in London and eventually traced them to a single contaminated well and water pump in the Soho district of the city.

In addition to writing several best - selling books like The Road Ahead, The Bill and Melinda Gates Foundation has raised billions of dollars to combat infectious diseases and elevate the quality of life for impoverished nations around the globe.

The idea behind the pills is simple: foster the growth of beneficial bacteria in the gut and curb the growth of the bad bacteria to improve digestion, boost the immune system, and even lower rates of certain diseases.